1-20 of 28
Victor M. Rivera, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Development and Validation of a Highly Sensitive e1a2 (p190) BCR-ABL Test to Determine Complete Molecular Response (Minimal Residual Disease Negative) As a Primary Endpoint for Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Kristy Drafahl, David C Smith, Cristen Graham, Christine Glynn, Cindy Spittle, Scott Verrow, Victor M. Rivera, PhD, Shouryadeep Srivastava, MBBS, PhD, Kevin Hawkins, Chad Galderisi, DO
Journal: Blood
Blood (2018) 132 (Supplement 1): 1558.
https://doi.org/10.1182/blood-2018-99-113172
Published: 2018
Journal Articles

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Andreas Hochhaus, MD, Jorge E. Cortes, MD, Dong-Wook Kim, MD PhD, Javier Pinilla-Ibarz, MD PhD, Philipp D. le Coutre, MD, Ronald Paquette, MD, Charles Chuah, MD, Franck Emmanuel Nicolini, MD PhD, Moshe Talpaz, MD, Daniel J. DeAngelo, MD, Elisabetta Abruzzese, MD PhD, Delphine Rea, MD, Martin C. Mueller, MD, Carlo Gambacorti-Passerini, MD, Fausto Castagnetti, MD PhD, Dragana Milojkovic, MBBS, PhD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Frank Neumann, MD PhD, Francois Guilhot, MD, Michael W. Deininger, MD PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Neil P. Shah, MD PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1617.
https://doi.org/10.1182/blood.V130.Suppl_1.1617.1617
Published: 2017
Journal Articles

Ponatinib in Chronic-Phase Chronic Myeloid Leukemia Patients: Final Report from a Phase 1 Trial

Michael J. Mauro, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Neil P. Shah, MD PhD, Dale L. Bixby, MD, Ian W. Flinn, MD PhD, Thomas O'Hare, PhD, Victor M. Rivera, PhD, Stephanie Lustgarten, PhD, Sergio Santillana, MD, Michael C. Heinrich, Brian J. Druker, MD, Michael W. Deininger, MD PhD, Moshe Talpaz, MD
Journal: Blood
Blood (2016) 128 (22): 3063.
https://doi.org/10.1182/blood.V128.22.3063.3063
Published: 2016
Journal Articles

Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation

Elias J. Jabbour, MD, Jorge E. Cortes, MD, Moshe Talpaz, MD, Michele Baccarani, MD, Michael J. Mauro, MD, Andreas Hochhaus, MD, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Francois Guilhot, MD, Michael W. Deininger, MD PhD, Neil Shah, MD PhD, Dale L. Bixby, MD, Ian W. Flinn, MD PhD, Thomas O'Hare, PhD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Sergio Santillana, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2016) 128 (22): 3067.
https://doi.org/10.1182/blood.V128.22.3067.3067
Published: 2016
Journal Articles

Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with Ponatinib

Justin R. Pritchard, PhD, Michael W. Schmitt, MD PhD, J. Graeme Hodgson, PhD, Stephanie Lustgarten, PhD, Shijie Tang, PhD, Lawrence A. Loeb, MD PhD, Jerald P. Radich, MD, Victor M. Rivera, PhD
Journal: Blood
Blood (2016) 128 (22): 1061.
https://doi.org/10.1182/blood.V128.22.1061.1061
Published: 2016
Journal Articles

Emergence of Sub-Clonal Drug Resistance Mutations during CML Therapy

Michael W. Schmitt, MD PhD, Justin R. Pritchard, PhD, Graeme Hodgson, PhD, Victor M. Rivera, PhD, Bella I. Aminov, Lan Beppu, Lawrence A. Loeb, MD PhD, Jerald P. Radich
Journal: Blood
Blood (2015) 126 (23): 478.
https://doi.org/10.1182/blood.V126.23.478.478
Published: 2015
Journal Articles

Detection of BCR-ABL1 Compound and Polyclonal Mutants in Chronic Myeloid Leukemia Patients Using a Novel Next Generation Sequencing Approach That Minimises PCR and Sequencing Errors

Wendy T Parker, PhD, Stuart R Phillis, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, David Lawrence, BCS, Andreas Schreiber, PhD, Paul Wang, PhD, Joel Geoghegan, MSc, Stephanie Lustgarten, PhD, Graeme Hodgson, Victor M. Rivera, PhD, Timothy P. Hughes, MD, Hamish Scott, PhD, Susan Branford, PhD
Journal: Blood
Blood (2014) 124 (21): 399.
https://doi.org/10.1182/blood.V124.21.399.399
Published: 2014
Journal Articles

Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events

Victor M. Rivera, PhD, Justin R. Pritchard, PhD, Francois Gonzalvez, PhD, Theresa Baker, Joseph M. Gozgit, PhD, Graeme Hodgson, PhD
Journal: Blood
Blood (2014) 124 (21): 1783.
https://doi.org/10.1182/blood.V124.21.1783.1783
Published: 2014
Journal Articles

Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Javier Pinilla-Ibarz, MD, PhD, Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Philipp D. Le Coutre, MD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane F Apperley, MD, H. Jean Khoury, MD, John F. Dipersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, Francois Guilhot, MD, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, DM, Neil P. Shah, MD, PhD, Hagop M. Kantarjian, MD, Moshe Talpaz, MD
Journal: Blood
Blood (2013) 122 (21): 4007.
https://doi.org/10.1182/blood.V122.21.4007.4007
Published: 2013
Journal Articles

Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial

Andreas Hochhaus, MD, Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Philipp D le Coutre, MD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane F Apperley, MD, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C. Müller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, Michael W. Deininger, MD, PhD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil P. Shah, MD, PhD, Hagop M. Kantarjian, MD, François Guilhot, MD
Journal: Blood
Blood (2013) 122 (21): 1498.
https://doi.org/10.1182/blood.V122.21.1498.1498
Published: 2013
Journal Articles

Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial

Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Philipp D. le Coutre, MD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane F. Apperley, MD, H Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J. DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C. Müller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, Frank G. Haluska, MD, PhD, Francois Guilhot, MD, Michael W. Deininger, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M. Goldman, MD, Neil P. Shah, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2738.
https://doi.org/10.1182/blood.V122.21.2738.2738
Published: 2013
Journal Articles

Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial

Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Philipp D le Coutre, MD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD PhD, Jane F Apperley, MD, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C. Müller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, François Guilhot, MD, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil P. Shah, MD, PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2013) 122 (21): 650.
https://doi.org/10.1182/blood.V122.21.650.650
Published: 2013
Journal Articles

Additional BCR-ABL1 Mutations Identified By Sensitive Mass Spectrometry In Chronic Phase CML Patients With T315I Treated With Ponatinib Are Associated With Relatively Inferior Responses and Outcome

Wendy T Parker, PhD, Alexandra L Yeoman, BSc, Haley Altamura, BSc, Nicola Roberts, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Bronte A Jamison, BSc, Chani Field, BSc, Stephanie Lustgarten, PhD, Graeme Hodgson, PhD, Victor M. Rivera, PhD, Timothy P. Hughes, MD, MBBS, Susan Branford, PhD
Journal: Blood
Blood (2013) 122 (21): 651.
https://doi.org/10.1182/blood.V122.21.651.651
Published: 2013
Journal Articles

Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Michael W. Deininger, MD, PhD, Neil P. Shah, MD, PhD, Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Franck E. Nicolini, MD, PhD, Moshe Talpaz, MD, Michele Baccarani, MD, Martin C Muller, MD, Jin Li, Stephanie Lustgarten, PhD, Tim Clackson, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, Graeme Hodgson, PhD, Victor M. Rivera, PhD, Francois Guilhot, MD, John M Goldman, DM, Hagop M. Kantarjian, MD, Simona Soverini, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, Susan Branford, PhD
Journal: Blood
Blood (2013) 122 (21): 652.
https://doi.org/10.1182/blood.V122.21.652.652
Published: 2013
Journal Articles

Comprehensive Analysis Of The In Vitro Potency Of Ponatinib, and All Other Approved BCR-ABL Tyrosine Kinase Inhibitors (TKIs), Against a Panel Of Single and Compound BCR-ABL Mutants

Joseph M Gozgit, PhD, Alexa Schrock, PhD, Tzu-Hsiu Chen, Tim Clackson, PhD, Victor M. Rivera, PhD
Journal: Blood
Blood (2013) 122 (21): 3992.
https://doi.org/10.1182/blood.V122.21.3992.3992
Published: 2013
Journal Articles

Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial

Dong-Wook Kim, Jorge E. Cortes, MD, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel DeAngelo, MD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M. Kantarjian, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 3749.
https://doi.org/10.1182/blood.V120.21.3749.3749
Published: 2012
Journal Articles

Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial

Andreas Hochhaus, MD, Dong-Wook Kim, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel DeAngelo, MD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, Martin C Muller, MD, Carlo Gambacorti-Passerini, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 3763.
https://doi.org/10.1182/blood.V120.21.3763.3763
Published: 2012
Journal Articles

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Michael W Deininger, MD, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Neil Shah, MD, PhD, Dale Bixby, MD, PhD, Michael J. Mauro, MD, Ian W. Flinn, MD, PhD, Thomas O'Hare, PhD, Simin Hu, PhD, David J. Dorer, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Brian J. Druker, Moshe Talpaz, MD
Journal: Blood
Blood (2012) 120 (21): 3743.
https://doi.org/10.1182/blood.V120.21.3743.3743
Published: 2012
Journal Articles

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Michael J. Mauro, MD, Jorge E. Cortes, MD, Dong-Wook Kim, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, MD, FACP, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, David J. Dorer, Ronald Keith Knickerbocker, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy Hughes, MD, MBBS, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M. Kantarjian, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 3747.
https://doi.org/10.1182/blood.V120.21.3747.3747
Published: 2012
Journal Articles

Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

Hagop M. Kantarjian, MD, Dong-Wook Kim, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel DeAngelo, MD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John Goldman, DM, FRCP, FRCPath, FMedSci, Neil Shah, MD, PhD, Jorge E. Cortes, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 915.
https://doi.org/10.1182/blood.V120.21.915.915
Published: 2012